The European Commission granted conditional approval to BioMarin's Hemophilia A gene therapy Valoctocogene Roxaparvovec which will be known as Roctavian.
With this approval in Europe the regulators will monitor the use of Valrox for 15 years to ensure safety of the therapy.
